Document Type : Original Article

Authors

1 School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Neurology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran

4 Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

5 Department of Neurology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran Neuromuscular Research Center, Tehran University of Medical Sciences, Tehran, Iran

6 Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran Department of Neurology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

7 Department of Neurology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

8 Department of Neurology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran

9 Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran AL Zahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

10 Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The Amyotrophic Lateral Sclerosis Cognitive Behavioral Screen (ALS-CBS) and the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) are widely recognized tools for evaluating cognitive, behavioral, and functional changes in patients with amyotrophic lateral sclerosis (ALS). Given the increasing number of ALS cases in Persian-speaking communities, there is a critical need for culturally and linguistically adapted versions of these instruments. The objective of this study was to translate the ALS-CBS and ALSFRS-R into Persian and evaluate their validity and reliability to ensure their applicability in clinical practice and research.
Methods: The Persian versions of the ALS-CBS and ALSFRS-R questionnaires were developed using the translation-back translation method. The translated questionnaires were administered to 36 individuals diagnosed with ALS. To assess content validity, neuromuscular specialists evaluated each item based on relevance, clarity, simplicity, necessity, and comprehensiveness, using content validity ratio (CVR) and content validity index (CVI) measures. Internal consistency reliability was assessed using Cronbach's alpha coefficient. Test-retest reliability was evaluated using the intra-class correlation coefficient (ICC). Statistical analysis was conducted using SPSS software.
Results: All questionnaire items demonstrated satisfactory face validity after expert-guided revisions. The minimum acceptable values for CVI (≥ 0.78) and CVR (≥ 0.62) were achieved by correcting items that initially scored below the threshold. Reliability analysis revealed ICC values of 0.969 and 0.816 for the cognitive and behavioral sections of the ALS-CBS, respectively, and 0.909 for the ALSFRS-R. Cronbach’s alpha coefficients were 0.791 for the ALS-CBS behavioral section and 0.825 for the ALSFRS-R, indicating acceptable internal consistency.
Conclusion: The Persian versions of the ALS-CBS and ALSFRS-R have been shown to be both valid and reliable. These adapted tools provide valuable resources for assessing the cognitive, behavioral, and functional status of patients with ALS in Persian-speaking populations, ultimately supporting more accurate diagnosis, monitoring, and disease management.

Keywords

Main Subjects

  1. EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis: Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol 2012; 19(3): 360-75.
  2. Hogden A, Foley G, Henderson RD, James N, Aoun SM. Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach. J Multidiscip Healthc 2017; 10: 205-15.
  3. Marin B, Boumédiene F, Logroscino G, Couratier P, Babron MC, Leutenegger AL, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol 2017; 46(1): 57-74.
  4. Sajjadi M, Etemadifar M, Nemati A, Ghazavi H, Basiri K, Khoundabi B, et al. Epidemiology of amyotrophic lateral sclerosis in Isfahan, Iran. Eur J Neurol 2010; 17(7): 984-9.
  5. van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet 2017; 390(10107): 2084-98.
  6. Xu L, Liu T, Liu L, Yao X, Chen L, Fan D, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol 2020; 267(4): 944-53.
  7. Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, de Haan RJ. The cognitive profile of ALS: a systematic review and meta-analysis update. J Neurol Neurosurg Psychiatry 2016; 87(6): 611-9.
  8. Woolley SC, York MK, Moore DH, Strutt AM, Murphy J, Schulz PE, et al. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). Amyotroph Lateral Scler 2010; 11(3): 303-11.
  9. Hu WT, Shelnutt M, Wilson A, Yarab N, Kelly C, Grossman M, et al. Behavior matters--cognitive predictors of survival in amyotrophic lateral sclerosis. Plos One 2013; 8(2): e57584.
  10. Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18(5): 459-80.
  11. Logroscino G, Piccininni M, Marin B, Nichols E, Abd-Allah F, Abdelalim A, et al. Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17(12): 1083-97.
  12. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol 1996; 53(2): 141-7.
  13. Bakker LA, Schröder CD, van Es MA, Westers P, Visser-Meily JMA, van den Berg LH. Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model. J Neurol 2017; 264(7): 1413-20.
  14. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169(1-2): 13-21.
  15. Branco LM, Zanao T, De Rezende TJ, Casseb RF, Balthazar MF, Woolley SC, et al. Transcultural validation of the ALS-CBS Cognitive Section for the Brazilian population. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18(1-2): 60-7.
  16. Campos TS, Rodríguez-Santos F, Esteban J, Vázquez PC, Mora Pardina JS, Carmona AC. Spanish adaptation of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). Amyotroph Lateral Scler 2010; 11(5): 475-7.
  17. Manera U, Cabras S, Daviddi M, Vasta R, Torrieri MC, Palumbo F, et al. Validation of the Italian version of self-administered ALSFRS-R scale. Amyotroph Lateral Scler Frontotemporal Degener 2021; 22(1-2): 151-3.
  18. Turon-Sans J, Gascon-Bayarri J, Reñé R, Rico I, Gámez C, Paipa A, et al. Cognitive impairment in ALS patients and validation of the Spanish version of the ALS-CBS test. Amyotroph Lateral Scler Frontotemporal Degener 2016; 17(3-4): 221-7.
  19. López-Pina J-A, Veas A. Validation of Psychometric Instrumentswith Classical Test Theory in Social and Health Sciences: A practical guide. Anales de Psicología/Annals of Psychology 2024; 40(1): 163-70.
  20. Gosselt IK, Nijboer TCW, Van Es MA. An overview of screening instruments for cognition and behavior in patients with ALS: selecting the appropriate tool for clinical practice. Amyotroph Lateral Scler Frontotemporal Degener 2020; 21(5-6): 324-36.
  21. Lawshe CH. A quantitative approach to content validity. Pers Psychol 1975; 28(4): 563-75.
  22. Afrakhteh M, Esmaeili S, Shati M, Shojaei SF, Bahadori M, Zamani B, et al. Validating the Persian version of the amyotrophic lateral sclerosis-specific quality of life-revised instrument. Curr J Neurol 2021; 20(1): 37-42.
  23. Mojtabavi H, Nafissi S, Mahmoodi-Bakhtiari B, Fathi D, Fatehi F. Persian adaptation of Edinburgh Cognitive and Behavioural Screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener 2021; 22(5-6): 426-33.
  24. Shamshiri H, Eshraghian MR, Ameli N, Nafissi S. Validation of the Persian version of the 40-item amyotrophic lateral sclerosis assessment questionnaire. Iran J Neurol 2013; 12(3): 102-5.
  25. Rahimzadeh Goradel R, Sattarpour R, Hooshyari Z, Taebi M, Ghavampour A, Jazani MR, et al. Examining the validity and reliability of the Persian version of the MiND-B questionnaire in ALS patients. Brain Behav 2023; 13(9): e3167.
  26. Benjaminsen E, Alstadhaug KB, Gulsvik M, Baloch FK, Odeh F. Amyotrophic lateral sclerosis in Nordland county, Norway, 2000-2015: prevalence, incidence, and clinical features. Amyotroph Lateral Scler Frontotemporal Degener 2018; 19(7-8): 522-7.
  27. Jun KY, Park J, Oh KW, Kim EM, Bae JS, Kim I, et al. Epidemiology of ALS in Korea using nationwide big data. J Neurol Neurosurg Psychiatry 2019; 90(4): 395-403.
  28. Longinetti E, Regodón Wallin A, Samuelsson K, Press R, Zachau A, Ronnevi LO, et al. The Swedish motor neuron disease quality registry. Amyotroph Lateral Scler Frontotemporal Degener 2018; 19(7-8): 528-37.
  29. Tang W, Cui Y, Babenko O. Internal consistency: Do we really know what it is and how to assess it. J Psychol Behav Sci 2014; 2(2): 205-20.
  30. Bujang MA, Omar ED, Baharum NA. A Review on Sample Size Determination for Cronbach's Alpha Test: A Simple Guide for Researchers. Malays J Med Sci 2018; 25(6): 85-99.
  31. Rashed HR, Tork MA, Soliman R, Serag R, Fahmy N. Arabic adaptation and validation of the revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R): Egyptian study. Amyotroph Lateral Scler Frontotemporal Degener 2021; 22(3-4): 220-2.
  32. Brylev L, Demeshonok VS, Ataulina AI, Kovalchuk MO, Druzhinin DS, Guekht AB. Validity and reliability of the Russian version of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). Neurol Sci 2024; 45(1): 187-9.
  33. Koç F, Balal M, Demir T, Alparslan ZN, Sarica Y. Adaptation to Turkish and Reliability Study of the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). Noro Psikiyatr Ars 2016; 53(3): 229-33.
  34. Ohashi Y, Tashiro K, Itoyama Y, Nakano I, Sobue G, Nakamura S, et al. [Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS(ALSFRS-R) Japanese version]. No To Shinkei 2001; 53(4): 346-55.
  35. Tremolizzo L, Lizio A, Santangelo G, Diamanti S, Lunetta C, Gerardi F, et al. ALS Cognitive Behavioral Screen (ALS-CBS): normative values for the Italian population and clinical usability. Neurol Sci 2020; 41(4): 835-41.
  36. Aiello EN, Greco LC, La Tona A, Solca F, Torre S, Carelli L, et al. Clinimetrics of the cognitive section of the Italian ALS Cognitive Behavioral Screen (ALS-CBS™). Neurol Sci 2023; 44(4): 1243-9.
  37. Aiello EN, Solca F, Greco LC, La Tona A, Torre S, Carelli L, et al. Standardization of the Italian ALS-CBS™ Caregiver Behavioral Questionnaire. Front Psychol 2022; 13: 1107001.
  38. Aiello EN, Solca F, Greco LC, Torre S, Carelli L, Morelli C, et al. Equating norms between the ALS Cognitive Behavioral Screen (ALS-CBS™) and the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) in non-demented ALS patients. J Neurol 2023; 270(8): 4090-5.
  39. Aiello EN, Torre S, Solca F, Curti B, De Luca G, Gendarini C, et al. Ecological validity of performance-based cognitive screeners in amyotrophic lateral sclerosis: preliminary evidence. Neurol Sci 2024; 45(11): 5319-25.